-
1
-
-
0041435762
-
-
Atlanta, Ga: American Cancer Society
-
American Cancer Society. Cancer Facts and Figures 2010. Atlanta, Ga: American Cancer Society; 2010.
-
(2010)
Cancer Facts and Figures 2010
-
-
-
2
-
-
28344454000
-
Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
-
Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-7360.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7350-7360
-
-
Brenton, J.D.1
Carey, L.A.2
Ahmed, A.A.3
Caldas, C.4
-
3
-
-
70249123890
-
Biology, metastatic patterns and treatment of patients with triple-negative breast cancer
-
Anders CK, Carey LA. Biology, metastatic patterns and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009;9:S73-S81.
-
(2009)
Clin Breast Cancer
, vol.9
, pp. S73-S81
-
-
Anders, C.K.1
Carey, L.A.2
-
5
-
-
84937582167
-
Effect of triple-negative status on surgical decision making
-
Crutcher CL, Cornwell LB, Chagpar AB. Effect of triple-negative status on surgical decision making. ASCO 2010.
-
(2010)
ASCO
-
-
Crutcher, C.L.1
Cornwell, L.B.2
Chagpar, A.B.3
-
6
-
-
61449142636
-
Local-Regional Recurrence of Triple Negative Breast Cancer after Breast-Conserving Surgery and Radiation
-
Freedman GM, Anderson PR, Li T, Nicolaou N. Local-Regional Recurrence of Triple Negative Breast Cancer after Breast-Conserving Surgery and Radiation. Cancer 2009;115:946-951.
-
(2009)
Cancer
, vol.115
, pp. 946-951
-
-
Freedman, G.M.1
Anderson, P.R.2
Li, T.3
Nicolaou, N.4
-
7
-
-
78449311361
-
Triple-negative breast cancer: epidemiology and management options
-
Dawood S. Triple-negative breast cancer: epidemiology and management options. Drugs 2010:70:2247-2258.
-
(2010)
Drugs
, vol.70
, pp. 2247-2258
-
-
Dawood, S.1
-
8
-
-
79960845909
-
Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation
-
Panoff JE, Hurley J, Takita C, Reis IM, Zhao W, Sujoy V, et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat 2011;128:899-906.
-
(2011)
Breast Cancer Res Treat
, vol.128
, pp. 899-906
-
-
Panoff, J.E.1
Hurley, J.2
Takita, C.3
Reis, I.M.4
Zhao, W.5
Sujoy, V.6
-
9
-
-
79960714832
-
Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy
-
Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011;29:2852-2858.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2852-2858
-
-
Abdulkarim, B.S.1
Cuartero, J.2
Hanson, J.3
Deschênes, J.4
Lesniak, D.5
Sabri, S.6
-
10
-
-
77955010884
-
A review of triple-negative breast cancer
-
Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control 2010;17:173-176.
-
(2010)
Cancer Control
, vol.17
, pp. 173-176
-
-
Ismail-Khan, R.1
Bui, M.M.2
-
11
-
-
78649389607
-
Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
-
Berrada N, Delaloge S, André F. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol 2010;21 Suppl 7:vii30-vii35.
-
(2010)
Ann Oncol
, vol.21
, pp. vii30-vii35
-
-
Berrada, N.1
Delaloge, S.2
André, F.3
-
12
-
-
84881326651
-
Triple-negative breast cancer: an update on neoadjuvant clinical trials
-
Amos KD, Adamo B, Anders CK. Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer 2012;2012:385978.
-
(2012)
Int J Breast Cancer
, vol.2012
-
-
Amos, K.D.1
Adamo, B.2
Anders, C.K.3
-
13
-
-
77954335786
-
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v15-v19.
-
(2010)
Ann Oncol
, vol.21
, pp. v15-v19
-
-
Cardoso, F.1
Senkus-Konefka, E.2
Fallowfield, L.3
Costa, A.4
Castiglione, M.5
-
14
-
-
70849122251
-
Triple-negative breast cancer--current status and future directions
-
Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer--current status and future directions. Ann Oncol 2009;20:1913-1927.
-
(2009)
Ann Oncol
, vol.20
, pp. 1913-1927
-
-
Gluz, O.1
Liedtke, C.2
Gottschalk, N.3
Pusztai, L.4
Nitz, U.5
Harbeck, N.6
-
15
-
-
51849101768
-
Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease
-
Abstr 13.
-
Slamon D, Mackey J, Robert N, Crown J, Martin M, Eiremann W, et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. Breast Cancer Res Treat 2007;106:Abstr 13.
-
(2007)
Breast Cancer Res Treat
, vol.106
-
-
Slamon, D.1
Mackey, J.2
Robert, N.3
Crown, J.4
Martin, M.5
Eiremann, W.6
-
16
-
-
38049103907
-
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of andomized trials
-
Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of andomized trials. J Natl Cancer Inst 2008;100:14-20.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 14-20
-
-
Gennari, A.1
Sormani, M.P.2
Pronzato, P.3
Puntoni, M.4
Colozza, M.5
Pfeffer, U.6
-
17
-
-
0141954010
-
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis
-
Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221-6228.
-
(2003)
Cancer Res
, vol.63
, pp. 6221-6228
-
-
Quinn, J.E.1
Kennedy, R.D.2
Mullan, P.B.3
Gilmore, P.M.4
Carty, M.5
Johnston, P.G.6
-
18
-
-
33847136743
-
Triple-negative breast cancer: therapeutic options
-
Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-244.
-
(2007)
Lancet Oncol
, vol.8
, pp. 235-244
-
-
Cleator, S.1
Heller, W.2
Coombes, R.C.3
-
19
-
-
0035866772
-
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
-
Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Research 2001;61:2505-2512.
-
(2001)
Cancer Research
, vol.61
, pp. 2505-2512
-
-
Geisler, S.1
Lonning, P.E.2
Aas, T.3
Johnsen, H.4
Fluge, O.5
Haugen, D.F.6
-
20
-
-
55849132481
-
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases
-
Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008; 113:2638-2645.
-
(2008)
Cancer
, vol.113
, pp. 2638-2645
-
-
Lin, N.U.1
Claus, E.2
Sohl, J.3
Razzak, A.R.4
Arnaout, A.5
Winer, E.P.6
-
21
-
-
65649151690
-
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design
-
Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009;9:29-33.
-
(2009)
Clin Breast Cancer
, vol.9
, pp. 29-33
-
-
Kassam, F.1
Enright, K.2
Dent, R.3
Dranitsaris, G.4
Myers, J.5
Flynn, C.6
-
22
-
-
80051509468
-
Emerging trends in treatment of TNBC
-
Verma S, Provencher L, Dent R. Emerging trends in treatment of TNBC. Curr Oncol 2011;18:180-190.
-
(2011)
Curr Oncol
, vol.18
, pp. 180-190
-
-
Verma, S.1
Provencher, L.2
Dent, R.3
-
23
-
-
33847063053
-
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
-
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-2334.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2329-2334
-
-
Carey, L.A.1
Dees, E.C.2
Sawyer, L.3
Gatti, L.4
Moore, D.T.5
Collichio, F.6
-
24
-
-
77955711844
-
47% pathologic complete response rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients
-
Abstr 4010.
-
Le Tourneau C, Dettwiler S, Laurence V, Alran S, Beuzeboc P, Pierga JY, et al. 47% pathologic complete response rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients. Breast Cancer Res Treat 2007;106:Abstr 4010.
-
(2007)
Breast Cancer Res Treat
, vol.106
-
-
Le Tourneau, C.1
Dettwiler, S.2
Laurence, V.3
Alran, S.4
Beuzeboc, P.5
Pierga, J.Y.6
-
25
-
-
79959826175
-
Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer
-
Wang S, Yang H, Tong F, Zhang J, Yang D, Liu H, et al. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. Gan To Kagaku Ryoho 2009;36:255-258.
-
(2009)
Gan To Kagaku Ryoho
, vol.36
, pp. 255-258
-
-
Wang, S.1
Yang, H.2
Tong, F.3
Zhang, J.4
Yang, D.5
Liu, H.6
-
26
-
-
39149111633
-
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
-
Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-785.
-
(2008)
J Clin Oncol
, vol.26
, pp. 778-785
-
-
Rastogi, P.1
Anderson, S.J.2
Bear, H.D.3
Geyer, C.E.4
Kahlenberg, M.S.5
Robidoux, A.6
-
27
-
-
23844549918
-
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
-
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 5678-5685
-
-
Rouzier, R.1
Perou, C.M.2
Symmans, W.F.3
Ibrahim, N.4
Cristofanilli, M.5
Anderson, K.6
-
28
-
-
0038147067
-
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
-
Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285-1291.
-
(2003)
Br J Cancer
, vol.88
, pp. 1285-1291
-
-
Tassone, P.1
Tagliaferri, P.2
Perricelli, A.3
Blotta, S.4
Quaresima, B.5
Martelli, M.L.6
-
30
-
-
0034604716
-
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
-
Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-23903.
-
(2000)
J Biol Chem
, vol.275
, pp. 23899-23903
-
-
Bhattacharyya, A.1
Ear, U.S.2
Koller, B.H.3
Weichselbaum, R.R.4
Bishop, D.K.5
-
31
-
-
34548410083
-
Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC)
-
(Abstr 3074).
-
Garber J, Richardson A, Harris L, Mironn A, Silver D, Golshan M, et al. Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC). Breast Cancer Res Treat 2006;100:S149 (Abstr 3074).
-
(2006)
Breast Cancer Res Treat
, vol.100
, pp. S149
-
-
Garber, J.1
Richardson, A.2
Harris, L.3
Mironn, A.4
Silver, D.5
Golshan, M.6
-
32
-
-
1942424876
-
Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients
-
Ezzat AA, Ibrahim EM, Ajarim DS, Rahal MM, Raja MA, Tulbah AM, et al. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer 2004;90:968-974.
-
(2004)
Br J Cancer
, vol.90
, pp. 968-974
-
-
Ezzat, A.A.1
Ibrahim, E.M.2
Ajarim, D.S.3
Rahal, M.M.4
Raja, M.A.5
Tulbah, A.M.6
-
33
-
-
67650382241
-
Preoperative weekly cisplatin-epirubicinpaclitaxel with G-CSF support in triple-negative large operable breast cancer
-
Frasci G, Comella P, Rinaldo M, Iodice G, Di Bonito M, D'Aiuto M, et al. Preoperative weekly cisplatin-epirubicinpaclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 2009;20:1185-1192.
-
(2009)
Ann Oncol
, vol.20
, pp. 1185-1192
-
-
Frasci, G.1
Comella, P.2
Rinaldo, M.3
Iodice, G.4
Di Bonito, M.5
D'Aiuto, M.6
-
34
-
-
80052882569
-
The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40
-
abstr LBA1005.
-
Bear HD, Tang G, Rastogi P, Geyer CE, Robidoux A, Atkins JN, et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol 2011;29:abstr LBA1005.
-
(2011)
J Clin Oncol
, vol.29
-
-
Bear, H.D.1
Tang, G.2
Rastogi, P.3
Geyer, C.E.4
Robidoux, A.5
Atkins, J.N.6
-
35
-
-
84873094077
-
Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers
-
Zelnak AB, Harichand-Herdt S, Styblo TM, Rizzo M, Gabram SG, Bumpers HL, et al. Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers. J Clin Oncol (Meeting Abstracts) 2011;29:1118.
-
(2011)
J Clin Oncol (Meeting Abstracts)
, vol.29
, pp. 1118
-
-
Zelnak, A.B.1
Harichand-Herdt, S.2
Styblo, T.M.3
Rizzo, M.4
Gabram, S.G.5
Bumpers, H.L.6
-
36
-
-
0028707977
-
Breast cancer outcome and predictors of outcome: are there age differentials?
-
Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 1994;(16):35-42.
-
(1994)
J Natl Cancer Inst Monogr
, Issue.16
, pp. 35-42
-
-
Albain, K.S.1
Allred, D.C.2
Clark, G.M.3
-
37
-
-
84887470910
-
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers: seconday endpoint analysis of the GeparQuinto study (GBG 44)
-
Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers: seconday endpoint analysis of the GeparQuinto study (GBG 44). Ann Oncol 2013;24:2978-2984.
-
(2013)
Ann Oncol
, vol.24
, pp. 2978-2984
-
-
Gerber, B.1
Loibl, S.2
Eidtmann, H.3
Rezai, M.4
Fasching, P.A.5
Tesch, H.6
-
38
-
-
79954495078
-
Abstract S4-6: Neoadjuvant chemotherapy with or without Bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44)
-
von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al. Abstract S4-6: Neoadjuvant chemotherapy with or without Bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44). Cancer Res 2010;70:S4-6.
-
(2010)
Cancer Res
, vol.70
, pp. S4-S6
-
-
von Minckwitz, G.1
Eidtmann, H.2
Rezai, M.3
Fasching, P.A.4
Tesch, H.5
Eggemann, H.6
-
39
-
-
45549107234
-
Novel cytotoxic agents: epothilones
-
Goodin S. Novel cytotoxic agents: epothilones. Am J Health Syst Pharm 2008;65:S10-S15.
-
(2008)
Am J Health Syst Pharm
, vol.65
, pp. S10-S15
-
-
Goodin, S.1
-
40
-
-
59149087388
-
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer
-
Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009;27:526-534.
-
(2009)
J Clin Oncol
, vol.27
, pp. 526-534
-
-
Baselga, J.1
Zambetti, M.2
Llombart-Cussac, A.3
Manikhas, G.4
Kubista, E.5
Steger, G.G.6
-
41
-
-
34547661993
-
Triple-negative breast cancer: clinical features and patterns of recurrence
-
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-4434.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 4429-4434
-
-
Dent, R.1
Trudeau, M.2
Pritchard, K.I.3
Hanna, W.M.4
Kahn, H.K.5
Sawka, C.A.6
-
42
-
-
36849035177
-
Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple-negative breast cancers?
-
Petit T, Wilt M, Rodier J, Muller D, Ghnassia J, Dufour P, et al. Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple-negative breast cancers? J Clin Oncol (Meeting Abstracts) 2007;25:580.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 580
-
-
Petit, T.1
Wilt, M.2
Rodier, J.3
Muller, D.4
Ghnassia, J.5
Dufour, P.6
-
43
-
-
84937563173
-
Use of molecular classification combined with p53 and topoisomerase IIa expression to identify tumors highly responsive to FEC regimen: a tissue microarray
-
Berrada N, Conforti R, Delaloge S, Spielmann M, Andre F. Use of molecular classification combined with p53 and topoisomerase IIa expression to identify tumors highly responsive to FEC regimen: a tissue microarray. J Clin Oncol (Meeting Abstracts) 2009;27:546.
-
(2009)
J Clin Oncol (Meeting Abstracts)
, vol.27
, pp. 546
-
-
Berrada, N.1
Conforti, R.2
Delaloge, S.3
Spielmann, M.4
Andre, F.5
-
44
-
-
77149129324
-
Anthracyclines in basal breast cancer: the NCICCTG trial MA5 comparing adjuvant CMF to CEF
-
abstr 519.
-
Cheang M, Chia SK, Tu D, Jiang S, Shepherd LE, Pritchard KI, et al. Anthracyclines in basal breast cancer: the NCICCTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 2009;27:abstr 519.
-
(2009)
J Clin Oncol
, vol.27
-
-
Cheang, M.1
Chia, S.K.2
Tu, D.3
Jiang, S.4
Shepherd, L.E.5
Pritchard, K.I.6
-
45
-
-
0037445132
-
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
-
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
-
(2003)
J Clin Oncol
, vol.21
, pp. 976-983
-
-
Henderson, I.C.1
Berry, D.A.2
Demetri, G.D.3
Cirrincione, C.T.4
Goldstein, L.J.5
Martino, S.6
-
46
-
-
42249083269
-
Weekly paclitaxel in the adjuvant treatment of breast cancer
-
Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-1671.
-
(2008)
N Engl J Med
, vol.358
, pp. 1663-1671
-
-
Sparano, J.A.1
Wang, M.2
Martino, S.3
Jones, V.4
Perez, E.A.5
Saphner, T.6
-
47
-
-
34248145042
-
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
-
Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 2006;8:R66.
-
(2006)
Breast Cancer Res
, vol.8
, pp. R66
-
-
Harris, L.N.1
Broadwater, G.2
Lin, N.U.3
Miron, A.4
Schnitt, S.J.5
Cowan, D.6
-
48
-
-
34547504504
-
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
-
Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 2007;104:12117-12122.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 12117-12122
-
-
Rottenberg, S.1
Nygren, A.O.2
Pajic, M.3
Van Leeuwen, F.W.4
Van Der Heijden, I.5
Van De Wetering, K.6
-
49
-
-
62549091454
-
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial
-
Hugh J, Hanson J, Cheang MCU, Nielsen TO, Perou CM, Dumontet C, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009;27:1168-1176.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1168-1176
-
-
Hugh, J.1
Hanson, J.2
Cheang, M.C.U.3
Nielsen, T.O.4
Perou, C.M.5
Dumontet, C.6
-
50
-
-
65649108950
-
Adjuvant chemotherapy in older women with early-stage breast cancer
-
Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360:2055-2065.
-
(2009)
N Engl J Med
, vol.360
, pp. 2055-2065
-
-
Muss, H.B.1
Berry, D.A.2
Cirrincione, C.T.3
Theodoulou, M.4
Mauer, A.M.5
Kornblith, A.B.6
-
51
-
-
84937549394
-
Abstract S4-1: FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer
-
S4-1.
-
Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, et al. Abstract S4-1: FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer. Cancer Res 2010;70:S4-1.
-
(2010)
Cancer Res
, vol.70
-
-
Joensuu, H.1
Kellokumpu-Lehtinen, P.L.2
Huovinen, R.3
Jukkola-Vuorinen, A.4
Tanner, M.5
-
52
-
-
67049142413
-
Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies
-
Abstract nr 3057.
-
Rugo HS, Roche H, Thomas E, Blackwell K, Chung H, Lerzo G, et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. Cancer Res 2009;69:Abstract nr 3057.
-
(2009)
Cancer Res
, vol.69
-
-
Rugo, H.S.1
Roche, H.2
Thomas, E.3
Blackwell, K.4
Chung, H.5
Lerzo, G.6
-
53
-
-
0037099533
-
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial
-
Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002; 20:3114-3121.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3114-3121
-
-
Biganzoli, L.1
Cufer, T.2
Bruning, P.3
Coleman, R.4
Duchateau, L.5
Calvert, A.H.6
-
54
-
-
48349109492
-
Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations
-
Wysocki PJ, Korski K, Lamperska K, Zaluski J, Mackiewicz A. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit 2008;14:SC7-SC10.
-
(2008)
Med Sci Monit
, vol.14
, pp. SC7-SC10
-
-
Wysocki, P.J.1
Korski, K.2
Lamperska, K.3
Zaluski, J.4
Mackiewicz, A.5
-
55
-
-
77149126252
-
Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC)
-
abstr 1099.
-
Byrski T, Foszczynska-Kloda M, Huzarski T, Dent R, Gronwald J, Cybulski C, et al. Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC). J Clin Oncol 2009;27:abstr 1099.
-
(2009)
J Clin Oncol
, vol.27
-
-
Byrski, T.1
Foszczynska-Kloda, M.2
Huzarski, T.3
Dent, R.4
Gronwald, J.5
Cybulski, C.6
-
56
-
-
38149059734
-
'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials
-
Kilburn LS; TNT Trial Management Group. 'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials. Clin Oncol (R Coll Radiol) 2008;20:35-39.
-
(2008)
Clin Oncol (R Coll Radiol)
, vol.20
, pp. 35-39
-
-
Kilburn, L.S.1
-
57
-
-
0037096755
-
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results
-
O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
-
(2002)
J Clin Oncol
, vol.20
, pp. 2812-2823
-
-
O'Shaughnessy, J.1
Miles, D.2
Vukelja, S.3
Moiseyenko, V.4
Ayoub, J.P.5
Cervantes, G.6
-
58
-
-
33847138943
-
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
-
Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007;8:219-225.
-
(2007)
Lancet Oncol
, vol.8
, pp. 219-225
-
-
Martín, M.1
Ruiz, A.2
Muñoz, M.3
Balil, A.4
García-Mata, J.5
Calvo, L.6
-
59
-
-
50549096593
-
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment
-
Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3950-3957.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3950-3957
-
-
Albain, K.S.1
Nag, S.M.2
Calderillo-Ruiz, G.3
Jordaan, J.P.4
Llombart, A.C.5
Pluzanska, A.6
-
60
-
-
55949092708
-
High sensitivity ofBRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
-
Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity ofBRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105:17079-17084.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 17079-17084
-
-
Rottenberg, S.1
Jaspers, J.E.2
Kersbergen, A.3
van der Burg, E.4
Nygren, A.O.5
Zander, S.A.6
-
61
-
-
17244373777
-
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
-
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
-
(2005)
Nature
, vol.434
, pp. 917-921
-
-
Farmer, H.1
McCabe, N.2
Lord, C.J.3
Tutt, A.N.4
Johnson, D.A.5
Richardson, T.B.6
-
62
-
-
68449096428
-
Efficacy of BSI-201, a poly (ADPribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial
-
O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al. Efficacy of BSI-201, a poly (ADPribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol (Meeting Abstracts) 2009;27:3.
-
(2009)
J Clin Oncol (Meeting Abstracts)
, vol.27
, pp. 3
-
-
O'Shaughnessy, J.1
Osborne, C.2
Pippen, J.3
Yoffe, M.4
Patt, D.5
Monaghan, G.6
-
63
-
-
33746759725
-
Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy
-
Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Soto M, et al. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Recent Pat Anticancer Drug Discov 2006;1:39-53.
-
(2006)
Recent Pat Anticancer Drug Discov
, vol.1
, pp. 39-53
-
-
Cepeda, V.1
Fuertes, M.A.2
Castilla, J.3
Alonso, C.4
Quevedo, C.5
Soto, M.6
-
64
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
-
(2007)
N Engl J Med
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
Dickler, M.4
Cobleigh, M.5
Perez, E.A.6
-
65
-
-
54249120945
-
Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO
-
Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol (Meeting Abstracts) 2008;26:LBA1011.
-
(2008)
J Clin Oncol (Meeting Abstracts)
, vol.26
-
-
Miles, D.1
Chan, A.2
Romieu, G.3
Dirix, L.Y.4
Cortes, J.5
Pivot, X.6
-
66
-
-
70249097518
-
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
-
Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, et al. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer. J Clin Oncol (Meeting Abstracts) 2009;27:1005.
-
(2009)
J Clin Oncol (Meeting Abstracts)
, vol.27
, pp. 1005
-
-
Robert, N.J.1
Dieras, V.2
Glaspy, J.3
Brufsky, A.4
Bondarenko, I.5
Lipatov, O.6
-
67
-
-
77955893812
-
A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane
-
abstr CRA1004^.
-
Twelves C, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet PJ, et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010;28:abstr CRA1004^.
-
(2010)
J Clin Oncol
, vol.28
-
-
Twelves, C.1
Loesch, D.2
Blum, J.L.3
Vahdat, L.T.4
Petrakova, K.5
Chollet, P.J.6
-
68
-
-
84873525082
-
Nab technology: a drug delivery platform utilizing endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting
-
Oxford: PharmaVentures Ltd
-
Desai N. Nab technology: a drug delivery platform utilizing endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Oxford: PharmaVentures Ltd; 2007:37-41.
-
(2007)
, pp. 37-41
-
-
Desai, N.1
-
69
-
-
0036096946
-
Phase I and pharmacokinetic study of ABI-007,a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel
-
Ibrahim NK, Desai N, Legha S. Phase I and pharmacokinetic study of ABI-007,a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin Cancer Res 2002;8:1038-1044.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1038-1044
-
-
Ibrahim, N.K.1
Desai, N.2
Legha, S.3
-
70
-
-
32944482677
-
Phase III trial of nanoparticle albumin -bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
-
Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin -bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7794-7803
-
-
Gradishar, W.J.1
Tjulandin, S.2
Davidson, N.3
Shaw, H.4
Desai, N.5
Bhar, P.6
-
71
-
-
79960015997
-
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
-
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-2767.
-
(2011)
J Clin Invest
, vol.121
, pp. 2750-2767
-
-
Lehmann, B.D.1
Bauer, J.A.2
Chen, X.3
Sanders, M.E.4
Chakravarthy, A.B.5
Shyr, Y.6
-
72
-
-
20244365941
-
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
-
Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-759.
-
(2005)
Cell
, vol.120
, pp. 747-759
-
-
Beuvink, I.1
Boulay, A.2
Fumagalli, S.3
Zilbermann, F.4
Ruetz, S.5
O'Reilly, T.6
-
73
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
-
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
-
(2004)
N Engl J Med
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
Khayat, D.4
Bleiberg, H.5
Santoro, A.6
-
74
-
-
16244400108
-
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody
-
Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 2005;41:107-127.
-
(2005)
Drugs Today (Barc)
, vol.41
, pp. 107-127
-
-
Harding, J.1
Burtness, B.2
-
75
-
-
61349152550
-
EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer
-
Carey LA, Rugo HS, Marcom PK, Irvin W Jr, Ferraro M, Burrows E, et al. EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol (Meeting Abstracts) 2008;26:1009.
-
(2008)
J Clin Oncol (Meeting Abstracts)
, vol.26
, pp. 1009
-
-
Carey, L.A.1
Rugo, H.S.2
Marcom, P.K.3
Irvin, W.J.R.4
Ferraro, M.5
Burrows, E.6
|